SIBIONICS Unveils the World's Thinnest CGM, GS3, at ATTD 2025 in Amsterdam

The GS3 by SIBIONICS: A Revolutionary CGM

At the recent Advanced Technologies & Treatments for Diabetes (ATTD) 2025 conference held in Amsterdam, SIBIONICS made headlines by introducing the world's thinnest continuous glucose monitor (CGM), the GS3. This remarkable device showcases not only groundbreaking design but also innovative technology aimed at diabetes management.

A Game-Changer in Diabetes Management

The GS3 boasts an ultra-slim design measuring just 2.9 mm thick, equivalent to the size of a small coin, and weighs a mere 1.5 grams, making it almost imperceptible when worn. The CGM is quick to set up, with activation taking only three seconds. Its lightweight and compact nature means that users can seamlessly integrate it into their daily lives without any discomfort.

Advanced Connectivity and User-Friendly Features

One of the standout features of the GS3 is its versatility in connectivity options. Users can easily connect the device to various smartphones via three different connectivity methods and enjoy the quick pairing facilitated by its NFC technology. This ensures that data sharing is instantaneous, requiring only a simple tap.

Moreover, the device employs advanced AI capabilities that enhance users' understanding of their glucose data, promoting better self-management. This functionality is especially beneficial for children and the elderly, as the GS3 can connect directly to smartwatches and receivers tailored to their needs.

Algorithm Innovations for Enhanced Reliability

SIBIONICS is committed to improving the user experience through continuous updates to the GS3's algorithms, which strengthens the stability and accuracy of glucose monitoring. This ensures that individuals managing diabetes can trust their devices for crucial health readings.

Symposium Insights: Clinical Applications of CGM

The ATTD 2025 event also featured a dedicated symposium where experts presented research findings on the clinical applications of continuous glucose monitoring. Their discussions focused on how CGMs, like the GS3, differentiate glycemic profiles across diverse patient groups, paving the way for personalized diabetes treatments.

Additionally, the symposium introduced the Continuous Ketone Monitoring (CKM) system, with clinical experts sharing their preliminary findings on its potential impact on type 1 diabetes management for the first time.

SIBIONICS: Pioneering Medical Device Innovation

Founded in 2015, SIBIONICS is a leading player in the medical device industry, with bases in Shenzhen, China, and Irvine, California. The company is dedicated to advancing healthcare technologies, employing over 500 professionals, with a significant portion involved in research and development.

SIBIONICS aims to transform patient lives by enhancing their understanding of health conditions through the integration of cutting-edge biosensors, intelligent algorithms, and user-friendly software solutions. With the launch of the GS3, SIBIONICS continues to stand at the forefront of innovation in glucose monitoring, providing a more effective, lightweight, and intelligent monitoring experience for people living with diabetes.

For more information on the GS3 or to explore SIBIONICS' offerings, visit their official website.